<DOC>
	<DOCNO>NCT00721734</DOCNO>
	<brief_summary>The purpose study assess influence renal impairment carfilzomib patient Multiple Myeloma ( MM ) .</brief_summary>
	<brief_title>Study Safety Pharmacokinetics Carfilzomib Patients With Relapsed Refractory Multiple Myeloma Varying Degrees Renal Function</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>1 . Written inform consent accordance federal , local , institutional guideline 2 . Males females ≥ 18 year age 3 . Multiple Myeloma 4 . Documented relapsed progressive disease ( PD ) receive least two prior treatment regimen ( induction therapy autologous stem cell transplant maintenance consider single regimen ) , must achieve minimal response well least one regimens 5 . Current measurable disease , indicate one following : Serum Mprotein ≥ 0.5 g/dL Urine Mprotein ≥ 200 mg/24 hour Serum Free Light Chain ( FLC ) assay : Involved FLC level ≥ 10 mg/dL provide serum FLC ratio abnormal 6 . Life expectancy three month 7 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 02 8 . Adequate hepatic function , bilirubin &lt; 2 time upper limit normal ( ULN ) alanine aminotransferase ( ALT ) &lt; 3 time ULN 9 . Total white blood cell ( WBC ) count ≥ 2,000/mm³ 10 . Absolute neutrophil count ( ANC ) ≥ 1,000/mm³ 11 . Hemoglobin ≥ 7 gm/dL Subjects may receive red blood cell ( RBC ) transfusion supportive care erythropoietin darbepoetin accordance institutional guideline 12 . Platelet count ≥ 30,000/ mm³ 13 . Female subject childbearing potential must negative serum pregnancy test within seven day first dose agree use dual method contraception 3 month follow last dose drug . Post menopausal female ( &gt; 45 year old without menses &gt; 1 year ) surgically sterilize female exempt pregnancy test 14 . Male subject must use effective barrier method contraception study three month follow last dose sexually active female childbearing potential 1 . Glucocorticoid therapy dose equivalent prednisone ≥ 20 mg/day within 14 day prior first dose study drug 2 . POEMS syndrome ( polyneuropathy , organomegaly , endocrinopathy , monoclonal protein , skin change ) 3 . Plasma cell leukemia 4 . Chemotherapy approve investigative anticancer therapeutic , include steroid therapy dose define , within 14 day prior first dose study drug antibody therapy within 6 week prior first dose study drug 5 . Radiation therapy immunotherapy within 3 week prior first dose ; localize radiation therapy within 1 week prior first dose 6 . Participation investigational therapeutic study within 14 day prior first dose study drug 7 . Prior carfilzomib treatment 8 . Pregnant lactating female 9 . Major surgery within 3 week prior first dose study drug 10 . Congestive heart failure ( New York Heart Association Class III IV ) , symptomatic ischemia , conduction abnormality myocardial infarction three month prior first dose study drug 11 . Uncontrolled hypertension 12 . Recent history acute active infection require systemic antibiotic , antiviral , antifungal within two week prior first dose study drug 13 . Known suspected human immunodeficiency virus ( HIV ) infection , know HIV seropositivity 14 . Active hepatitis A , B , C infection 15 . Other malignancy within past 3 year except ) adequately treat basal cell squamous cell skin cancer , b ) carcinoma situ cervix , c ) prostate cancer &lt; Gleason Grade 7 stable prostate specific antigen ( PSA ) level 16 . Any clinically significant medical psychiatric disease condition , Investigator 's opinion , may interfere protocol adherence subject 's ability give inform consent 17 . Significant neuropathy ( Grade 3 , Grade 4 , Grade 2 pain ) time first dose and/or within 14 day prior enrollment 18 . Subjects require program oral hydration intravenous fluid hydration contraindicate , e.g. , due preexist pulmonary cardiac impairment 19 . Subjects pleural effusion require routine thoracentesis ascites require routine paracentesis 20 . Subjects know contraindication receive dexamethasone allopurinol 21 . Receipt granulocyte granulocyte/ macrophage colony stimulate factor ( GCSF GMCSF ) within 1 week prior first dose study drug 22 . Receipt pegylated GCSF within 2 week prior first dose study drug 23 . RBC platelet transfusion within 7 day prior first dose study drug 24 . Subjects know suspected cardiac amyloidosis 25 . Subjects myelodysplastic syndrome 26 . Subjects undergoing peritoneal dialysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Myeloma</keyword>
	<keyword>Renal Insufficiency</keyword>
	<keyword>Proteasome</keyword>
	<keyword>Hematological</keyword>
	<keyword>carfilzomib</keyword>
	<keyword>PR-171</keyword>
</DOC>